BODIPY-Caged Photoactivated Inhibitors of Cathepsin B Flip the Light Switch on Cancer Cell Apoptosis by Toupin, Nicholas P. et al.
Chemistry Publications Chemistry 
11-21-2019 
BODIPY-Caged Photoactivated Inhibitors of Cathepsin B Flip the 
Light Switch on Cancer Cell Apoptosis 
Nicholas P. Toupin 
Wayne State University 
Karan Arora 
Wayne State University 
Pradeep Shrestha 
Iowa State University, pradeeps@iastate.edu 
Julie A. Peterson 
Iowa State University, japete@iastate.edu 
Logan J. Fischer 
Iowa State University, lofisch@iastate.edu 
See next page for additional authors 
Follow this and additional works at: https://lib.dr.iastate.edu/chem_pubs 
 Part of the Medicinal-Pharmaceutical Chemistry Commons 
The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/
chem_pubs/1188. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html. 
This Article is brought to you for free and open access by the Chemistry at Iowa State University Digital Repository. 
It has been accepted for inclusion in Chemistry Publications by an authorized administrator of Iowa State 
University Digital Repository. For more information, please contact digirep@iastate.edu. 
BODIPY-Caged Photoactivated Inhibitors of Cathepsin B Flip the Light Switch on 
Cancer Cell Apoptosis 
Abstract 
Acquired resistance to apoptotic agents is a long-standing challenge in cancer treatment. Cathepsin B 
(CTSB) is an enzyme which, among many essential functions, promotes apoptosis during cellular stress 
through regulation of intracelllular proteolytic networks on the minute timescale. Recent data indicate that 
CTSB inhibition may be a promising method to steer cells away from apoptotic death towards necrosis, a 
mechanism of cell death that can overcome resistance to apoptotic agents, stimulate an immune 
response and promote anti-tumor immunity. Unfortunately, rapid and selective intracellular inactivation of 
CTSB has not been possible. However, here we report on the synthesis and characterization of 
photochemical and biological properties of BODIPY-caged inhibitors of CTSB that are cell permeable, 
highly selective and activated rapidly upon exposure to visible light. Intriguingly, these compounds display 
tunable photophysical and biological properties based on substituents bound directly to boron. 
Me2BODIPY-caged compound 8 displays the dual-action capability of light-accelerated CTSB inhibition 
and singlet oxygen production from a singular molecular entitiy. The dual-action capacity of 8 leads to a 
rapid necrotic response in MDA-MB-231 triple negative breast cancer cells with high phototherapeutic 
indexes (>30) and selectivity vs. non-cancerous cells that neither CTSB inhibition nor photosensitization 
gives alone. Our work confirms that singlet oxygen production and CTSB inactivation is highly synergistic 
and a promising method for killing cancer cells. Furthermore, our ability to trigger intracellular inactivation 
of CTSB with light will provide researchers with a powerful photochemical tool for probing biochemical 
processes on short timescales. 
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Abstract. Acquired resistance to apoptotic agents is a long-standing challenge in cancer treatment. Cathepsin 
B (CTSB) is an enzyme which, among many essential functions, promotes apoptosis during cellular stress 
through regulation of intracellular proteolytic networks on the minute timescale. Recent data indicate that 
CTSB inhibition may be a promising method to steer cells away from apoptotic death towards necrosis, a 
mechanism of cell death that can overcome resistance to apoptotic agents, stimulate an immune response and 
promote anti-tumor immunity. Unfortunately, rapid and selective intracellular inactivation of CTSB has not 
been possible.  However, here we report on the synthesis and characterization of photochemical and biological 
properties of BODIPY-caged inhibitors of CTSB that are cell permeable, highly selective and activated rapidly 
upon exposure to visible light. Intriguingly, these compounds display tunable photophysical and biological 
properties based on substituents bound directly to boron. Me2BODIPY-caged compound 8 displays the dual-
action capability of light-accelerated CTSB inhibition and singlet oxygen production from a singular molecular 
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entity. The dual-action capacity of 8 leads to a rapid necrotic response in MDA-MB-231 triple negative breast 
cancer cells with high phototherapeutic indexes (>30) and selectivity vs. non-cancerous cells that neither CTSB 
inhibition nor photosensitization gives alone. Our work confirms that singlet oxygen production and CTSB 
inactivation is highly synergistic and a promising method for killing cancer cells. Furthermore, this ability to 
trigger intracellular inactivation of CTSB with light provides researchers with a powerful photochemical tool 
for probing biochemical processes on short timescales.
Introduction. The cysteine protease cathepsin B (CTSB) is a crucial enzyme in biology with a broad scope of 
functions that include degradation of proteins and organelles, antigen presentation1 and execution of cell death 
pathways.2 Aberrant CTSB activity is associated with many human disease states, including obesity3 diabetes,4 
non-alcoholic fatty liver disease,5 pancreatitis6 and cancer.7, 8 In order to understand the role of CTSB in biology 
and also target human diseases, small molecule inhibitors of this protease have been aggressively pursued.9-11 
     CTSB inhibitors have served as indispensable chemical tools; some inhibitors, either alone or in 
combination with other agents, have shown promise as potential therapeutics in cell and animal models of 
human diseases.8, 12, 13 This class of small molecules includes reversible and irreversible inhibitors, where 
most contain chemical “warheads” that target the active site cysteine through covalent modification. To date, 
irreversible CTSB inhibitors based on epoxides, namely CA-074 (1)14 and its methyl ester prodrug form CA-
074-Me (2),15 have been the most widely used (Figure 1). CA-074 contains a carboxylic acid and is not cell 
permeable, whereas methyl ester 2 is. Compounds 1 and 2 are routinely used by researchers working in vitro 
to target extra- and intracellular activity of CTSB, respectively.16-21 Although it is widely assumed that 2 
undergoes rapid conversion to 1 in cells, careful studies have established that 2 is not a selective inhibitor of 
intracellular CTSB activity because it inactivates other cysteine proteases,22, 23 likely due to the slow 
hydrolysis of 2 by intracellular esterases and the poor selectivity of 2 for CTSB inactivation vs. other cysteine 
cathepsins.24 Although some potent and selective CTSB inhibitors have been developed,25-27 a major 
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drawback to the suite of small molecule tools currently available is that there is no method to rapidly and 
selectively inactivate CTSB inside cells. 
     CTSB is a prognostic biomarker for many types of cancer28, 29 and its intra- and extracellular activity is 
intimately linked to most steps of tumor progression including invasion, migration, metastasis, and 
angiogenesis.30-32 Given its broad range of functions inside and outside the cell, targeting intra- and 
extracellular proteolysis by CTSB may be necessary for effective cancer treatment. Furthermore, CTSB 
inhibition may need to be combined with other treatment modalities, such as chemotherapy, radiation or 
photodynamic therapy, to achieve successful outcomes.9, 33, 34 
Figure 1.  Structures of epoxysuccinyl inhibitors CA-074 (1) and the methyl ester prodrug CA-074-Me (2).
     Through positive selection of resistant cells, pharmacological agents that induce apoptosis can lead to rapid 
resistance and poor therapeutic outcomes during cancer treatment.35 In an effort to avoid these issues, 
researchers have renewed interest in agents that cause death by mechanisms other than apoptosis.36 Necrosis 
and its programmed counterpart necroptosis have garnered recent attention as promising strategies to overcome 
resistance to clinical apoptotic agents 37 stimulate the immune system38 and build anti-tumor immunity.39 
Recent data confirm that CTSB plays a major role in controlling the balance between apoptotic and necrotic 
death in cells under stress conditions. Importantly, active CTSB functions as an emergency brake to steer cells 
under stress away from necrosis towards apoptotic death.40, 41 CTSB carries out this function through rapid 
regulation of proteolytic networks on the minute timescale by inhibiting degradation of the pro-apoptotic 
proteins bid and bax and accelerating cleavage of the anti-apoptotic protein bcl-xl. Therefore, combining rapid, 
intracellular CTSB inhibition with another mechanism that induces cell stress has great potential to steer cells 
away from apoptotic death towards necrosis.
H
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2 = CA-074-Me (R = Me)
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     Here we report the synthesis, photochemical and biological characterization of BODIPY-caged CTSB 
inhibitors that are cell permeable and are activated rapidly with visible light. This study reports a new class of 
highly tunable chemical tools for investigating the role of intracellular CTSB activity. Our lead compound 
inactivates CTSB with >700-fold kinetic control under light vs. dark conditions and >200-fold selectivity over 
inactivation of the related cysteine protease cathepsin L (CTSL). In addition to control over CTSB inactivation 
through rapid photochemical uncaging, we demonstrate that the released BODIPY dye can act as a 
photosensitizer to generate singlet oxygen (1O2). Importantly, efficiencies of photorelease and 
photosensitization are highly tunable based on substituents bound directly to boron, which leads to control over 
the levels of cell death in breast cancer cells, with high phototherapeutic indexes and selectivity over normal 
breast epithelial cells. Collectively, our data show that synergistic and rapid CTSB inactivation and oxidative 
stress steer cancer cells towards necrotic death, a response that neither CTSB inhibition nor photosensitization 
gives alone.
Results and Discussion
     To develop photocaged CTSB inhibitors, we combined the highly potent and selective, but cell 
impermeable, inhibitor CA-074 (1)14 with BODIPY-based photocaging groups42-44 (Scheme 1A). BODIPY 
photocages are attractive because they release carboxylates when irradiated over a broad range of the visible 
spectrum which provides an advantage over most organic photocaging groups that require UV light for 
cleavage. Caging of the free carboxylic acid motif in 1 with BODIPY was expected to facilitate membrane 
permeability and slow inactivation by blocking key interactions of the free acid with the CTSB active site, 
much like the known methyl ester derivative CA-074-OMe (2).15 However, unlike 2, which is not selective 
amongst other cysteine cathepsins and undergoes slow conversion to 1 by intracellular esterases,22, 23 photolysis 
of a BODIPY-caged inhibitor was expected to facilitate rapid intracellular release of the potent and selective 
inhibitor 1. 
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Scheme 1. Synthesis of BODIPY-caged CA-074 inhibitors 7–9
Three BODIPY-caged CA-074 derivatives were prepared through carbodiimide coupling reactions between 1 
and the known BODIPY alcohols 3–5 to furnish caged inhibitors 7–9 (Scheme 1). Compounds 7–9 were 
characterized by 1H and 13C NMR and electronic absorbance spectroscopies and high-resolution mass 
spectrometry. BODIPY-caged derivatives 7–9 all absorb strongly from ~400–550 nm, with λmax values ranging 
from 515–522 nm (ε = 55,300–71,000 M–1cm–1, Figure S40).
     Photochemical investigations with 7–9 indicated that the efficiency of uncaging and photoactivated enzyme 
inhibition are highly tunable based on the nature of the boron substituent X (Scheme 1B). Photodecomposition 
quantum yields were determined in methanol upon irradiation with a Nd:YAG   laser (λirr = 532 nm) by 
following decomposition of 7–9  by electronic absorption spectroscopy. Compound 8 (X = Me) displayed a 
photodecomposition quantum yield of 2.46 ± 0.19%.  Photolysis of 8 with blue light (λirr = 460–470 nm) 
generated CA-074 (1) and alcohol 4, as judged by LCMS analysis. Interestingly, a photodecomposition 
quantum yield of 0.56 ± 0.02% was observed for the related Et derivative 9, which is almost 5 times less than 
the yield observed for 8.  The photodecomposition quantum yield observed for 7 (X = F) was significantly 
lower (0.19 ± 0.02%), which is almost 13 times smaller than the yield observed for 8. Collectively, these data 
are similar to previous observations for release of acetate from Me, Et and F BODIPY caging groups (eg. 6), 
N
B
N
X XMe
Me Me
Me
R'O
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DMAP
CH2Cl2
rt, dark
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confirming that the efficiency of uncaging is tunable based on the substituent X, and that photolysis of 
BODIPY-protected esters leads to carboxylic acid and BODIPY-derived alcohol byproducts.45 
     To further assess the photodissociative action of 7–9 we evaluated the ability of these compounds to 
inactivate purified CTSB before and after irradiation with visible light. Solutions of 7–9 (100 nM) in CTSB 
activity assay buffer were irradiated (λirr = 395–750 nm) for 1–30 min. Purified human CTSB was added and 
enzyme activities were determined at five time intervals of irradiation using the fluorogenic substrate Z-Arg-
Arg-AMC. Compound 8 shows 100% activity at t = 0, but after only 5 min of irradiation CTSB activity drops 
to < 1%. In contrast, CTSB is still active with 7 and 9 after 10 and 30 min of irradiation, respectively (Figure 
S15-S17). These data show that the rate of photochemical activation of the irreversible inhibitor is highly 
tunable based on the boron substituent X and establish compound 8 as a lead inhibitor
     In order to gain a more quantitative assessment of the levels of photochemical inhibitor activation, progress 
curve analysis was used to measure levels of rate acceleration for CTSB inactivation under light vs. dark 
conditions (Table 1). CTSB activity was monitored over time in the presence of the fluorogenic substrate Z-
Arg-Arg-AMC and varied amounts of inhibitor. Data were fit to a two-step model for irreversible inactivation 
(Figures S13–14).45, 46 The equilibrium constant for reversible association of the inhibitors with CTSB (Ki) and 
the rate constant for irreversible inactivation due to epoxide opening (kinact) were determined, where kinact/Ki 
represents the overall second order rate constant for enzyme inactivation. The second order rate constant for 1 
is in good agreement with literature values,46 and was the same within error under dark and light conditions 
(λirr = 395–750 nm), indicating that light alone does not affect CTSB activity (Entry 1). In contrast, 8 inactivates 
CTSB at a rate of 220 ± 20 x103 M-1 s-1 with light irradiation, which is 760 times faster than the rate observed 
in the dark (Entry 4). This large difference is due to weaker equilibrium binding of 8 with CTSB in the dark 
(Ki = 320  30 µM) vs. in the light (Ki = 0.51  0.09 µM), rather than changes in kinact, which were the same 
within error under light and dark conditions (Entry 4). The light to dark ratio for 8 is in good agreement with 
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relative rates of inactivation by acid 1 vs. ester 2, which differ by roughly three orders of magnitude.47 
Compound 8 inactivated CTSB ~50% more rapidly than 1 under light conditions, which may be due to 
inactivation of CTSB by reactive oxygen species (ROS) generated after release of 1 (vide infra). However, the 
control compound 6, which releases acetate and 4 upon photolysis, was not a potent inhibitor under light or 
dark conditions, indicating that the BODIPY photocaging group and its photochemical products were not 
dominant in the inactivation of CTSB by 8 (Entry 2).  Data for 9 in the dark (Entry 5) were within error of 8, 
which were both about 10 times smaller than the second order rate constant obtained for 7 (Entry 3), indicating 
that the nature of the boron substituent X does control inactivation of CTSB in the dark. Data for 7 and 9 in the 
light were not collected, due to partial release of 1 from both compounds after 15 min of irradiation. Cathepsin 
L (CTSL) inactivation experiments indicated that 8 is 220 times more selective for CTSB over CTSL under 
light conditions (Table S2), similar to 1.46   Compound 8 displayed  rate constants for inactivation of CTSL of 
1.0 ± 0.9 x103 M-1 s-1 and 10.0 ± 3.0 M-1 s-1 in the light and dark, respectively.
Table 1.  Irreversible inhibition of CTSB by 1, 6–9 [a]
Entry Compounds Light kinact (s-1) Light Ki (µM)
Light
kinact/Ki
( 103 M–1s–1)
Dark kinact (s-1) Dark Ki (µM)
Dark
kinact/Ki
( 103 M–1s–1)
Light/Dark 
Ratio[c]
1 1 1.1  0.1  10-1 7.8  0.3  10-1 140  10 1.0  0.1  10-1 8.1  0.3  10-1 130  10 1.1
2 6 1.7  1.0  10-2 1.8  0.4  103 0.0010  0.0003 1.7  0.8  10-2 1.4  0.5  103 0.0012  
0.0002
0.83
3 7 ndb ndb ndb 1.9  0.1  10-1 9.4  0.3  101 2.1  0.1 -
4 8 1.1  0.1  10-1 5.1  0.9  10-1 220  20 8.9  0.1  10-2 3.2  0.3  102 0.29  0.03 760
5 9 ndb ndb ndb 8.9  0.1  10-2 3.5  0.2  102 0.26  0.01 -
Page 8 of 23
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[a] Second-order µs for enzyme inactivation obtained from progress curve analysis with CTSB (4 nM), Z-Arg-Arg-AMC (100 M), 1 or 6–9 (5 nM – 50 M) in 0.4 
M acetate buffer, pH 5.5, <1% DMSO, 4 mM EDTA, 0.01% Triton X-100, DTT = 8 mM at 25 °C under dark or light conditions (tirr = 15 min, λirr = 395–750 nm). 
[b] Not determined due to partial release of 1 after 15 min irradiation. [c] Ratio of light kinact/Ki to dark kinact/Ki
     After confirming that 8 is a highly potent and selective inactivator of CTSB under light conditions, we 
sought to determine its ability to inactivate CTSB in cellulo. Triple-negative MDA-MB-231 breast cancer cells 
were treated with 8 (2.5 µM) and left in the dark or irradiated for 15 min with a LED panel designed for 96 
well plates (see S1, λirr = 460–470 nm).  Lysates were collected after 4 h, and activity of CTSB was determined. 
Data confirmed that intracellular CTSB was targeted with 8 and that the enzyme inactivated fully under light 
and dark conditions at 4 h in cells treated with 8 relative to vehicle control (Table S3). Even though a difference 
between CTSB activity under light vs. dark conditions was not observed after 4 h, visual inspection of cells 
treated with 8 and light indicated substantial rounding, an increase in granularity and notable cell detachment 
compared with treatment with 8 in the dark, suggesting that the combination of 8 and light was causing an 
immediate toxic effect in the MDA-MB-231 cells that was consistent with necrosis (vide infra) and warranted 
further investigation.
         EC50 determinations were carried out with MDA-MB-231 cells via the 3-(4,5- Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H- tetrazolium bromide (MTT) assay to quantify cell toxicities. First, the irradiation protocol was 
optimized. After only 1 min of irradiation (λirr = 460–470 nm), viability after 4 h was reduced to ~40% vs. 
DMSO vehicle upon treatment with 8 (10 M). After 5 min of irradiation, viabilities were reduced to <10% 
and were not reduced further with longer irradiation times. However, 15 min of irradiation was used in all 
subsequent experiments to maximize release of 1 from 8 at higher concentrations.  EC50 values were obtained 
for 2 and 6–8 at 4 and 72 h under light (λirr = 460–470 nm, t = 15 min) or in constant darkness (Table 2). At 4 
h, Me2BODIPY caged inhibitor 8 exhibits an EC50 value of 2.5 µM post irradiation (λirr = 460–470 nm, t = 15 
min) vs. >100 μM in the dark, giving a phototherapeutic index (PI) of > 40 (Entry 6). Interestingly, 2 (Entry 1) 
or 6 (Entry 3) alone or in equimolar combination (Entry 4) showed no toxicity at 50 µM under light or dark 
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conditions at 4 h. These data are consistent with 8 being resistant to rapid esterase cleavage in cells, because 
the combination of 2 and 6 would be expected to give the same products as 8 (1 and 4) if rapid esterase cleavage 
were occurring. EC50 values for 7 and 9 were also >100 µM (Entries 5 and 8), which correlates the rate of 
photochemical release of 1 from 7–9 with cell toxicity; only 8, which provides rapid and efficient release of 1 
causes cell death in the low µM-nM range. At 72 h, 8 gave an EC50 of 780 nM in the light versus 24 μM in the 
dark, with PI = 30 (Entry 6). Toxicity of 8 after 72 h in the dark was similar to 2 in the dark and light (Entry 
1), which is consistent with slow release of 1, likely from esterases, causing some level of growth arrest over 
long time periods. EC50 values were also determined for 2 (Entry 2) and 8 (Entry 7) using the normal human 
epithelial breast cells (MCF-10A). At 4 and 72 h, EC50 values for 8 in MCF-10A cells were 10.3 μM and 3.5 
μM respectively, indicating that 8 displayed a 4-fold higher selectivity towards cancer cells vs. normal 
epithelial cells at both time points with light irradiation.
Table 2.  EC50 values (µM) for 2, 6–9 against MDA-MB-231[a] and MCF-10A[b] cells at 4 and 72 h[c]
Entry Compound Light (4h) Dark (4h) PId (4h) Light (72h) Dark (72h) PI[d] (72h)
1 2[a] >100 >100 - 33 ± 8.7 21 ± 5.1 0.6
2 2[b] >100 >100 - 49 ± 0.5 49 ± 5.5 1.0
3 6[a] >50 >50 - >50 >50 -
4 2 + 6[a],[e] >50 >50 - nd[f] nd[f] -
5 7[a] >50 >50 - >50 >50 -
6 8[a] 2.5 ± 0.22 >100 >40 0.78 ± 0.14 24 ± 3.3 30
7 8[b] 10.3 ± 2.0 >100 >9 3.5 ± 1.3 27 ± 11.5 7.7
8 9[a] >50 >50 - >50 >50 -
[a,b] Cells were treated with compound 2, 6–9 for 5 min, then irradiated (t = 15 min, λirr = 460–470 nm) or left in the dark. [c] Cell viabilities were determined by 
MTT after 4 and 72 h. Data are average of three independent experiments using quadruplicate wells, errors are standard deviations. [d] PI = phototherapeutic index = 
ratio dark EC50/light EC50. [e] Cells were treated simultaneously with equimolar amounts of 2 and 6.  
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     Data from toxicity studies indicated that the combination of 8 and light were required to achieve cell death 
at low concentrations. BODIPY dyes have previously shown excellent photosensitization capacities.48 To 
investigate the role of ROS, cells were pretreated with ROS scavengers NaN3, which quenches 1O2, histidine 
(50 mM), which quenches hydroxyl radical and 1O2 to a lesser extent than NaN3,49 and mannitol (50 mM) 
which quenches hydroxyl radical, before treatment with 8 (10 µM) and light (λirr = 460–470 nm, t = 15 min) 
(Figure 2). Only NaN3 provided a high level of rescue, implicating 1O2 in the cell death mechanism. Further 
investigation showed that NaN3 (10–100 mM) provided a dose dependent rescue of cells treated with 8 (10 
µM) and light but did not rescue cells fully from death at the highest concentration tested, consistent with ROS 
playing a role, but not being solely responsible for, toxicity observed with 8 (Figure S26). 
Figure 2. Cell viabilities determined after 4 h by MTT upon pretreatment with ROS scavengers (50 mM) NaN3, 
mannitol, or histidine for 2 h, followed by vehicle (blue) or 8 (red, 10 µM) and light (t = 15 min, λirr = 460–
470 nm) Data are averages of three independent experiments, error bars are standard deviations. *** p<0.01 
Relating no quencher 8 dosed sample with Na Azide 8 dosed sample. ** p<0.05 Relating no quencher 8 dosed 
sample with mannitol or histidine 8 dosed sample.
     Generation of 1O2 was further corroborated with the probe 1,2-diphenylisobenzofuran (DPBF). Rates of 1O2 
generation relative to methylene blue were determined for compounds 4 and 6–9 under broad band irradiation 
(λirr = 500–750 nm) in isopropanol (Table 3).50 Wavelengths of light irradiation < 500 nm were excluded using 
a long pass filter to minimize autooxidation of DPBF that occurs in the absence of photosensitizer. As judged 
by DPBF depletion, alcohol 4, a photoproduct derived from 6 and 8, shows the highest rate of 1O2 generation 
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in the series, over double the rate of the efficient photosensitizer methylene blue (Entry 1). The rate of 1O2 
generation for 8 was roughly 1.5 times that of methylene blue (Entry 4), whereas the rate for 7 was roughly 
three times slower than methylene blue (Entry 3).  Interestingly, the relative rate for Et derivative 9 (Entry 5) 
was over 25 times slower than 8, even though both compounds contain alkyl substituents as X. Acetoxy 
Me2BODIPY derivative 6, which releases acetate upon photolysis,44 generates 1O2 at a rate roughly half that 
of 8 (Entry 2), suggesting that methyl groups provide optimal levels of 1O2 generation. Collectively, these data 
confirm that levels of 1O2 generation can be tuned over two orders of magnitude by changing the substituent 
X bound directly to boron.  Probably, the methyl groups on boron accelerate intersystem crossing to the triplet 
excited state, leading to singlet oxygen generation.  This idea is consistent with improved photorelease quantum 
yields for these compounds, since triplet excited states live longer than singlet excited states, providing an 
extended time window for the photocage to undergo photorelease.  Furthermore, data for 6 and 8 reveal that 
generation of 1O2 is not the only factor that contributes to cytotoxicity. The caged CTSB inhibitor 8 is >20 
times more potent than 6 alone or in combination with 2 under light conditions at 4 h. Given that 8 shows a 
rapid acceleration of CTSB inactivation under light vs. dark conditions (Table 1, Entry 4) and 6 does not (Table 
1, Entry 2), the rate of CTSB inactivation may contribute to the observed cytotoxicity.
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Table 3.  Rates of singlet oxygen generation, reported as percentages, relative to methylene blue determined 
by 1,2-diphenylisobenzofuran (DPBF) depletion [a}
Entry Compound Relative Rate of DPBF Degradation (%) [b]
1 4
202 ± 5
2 6
69 ± 18 
3 7
31.3 ± 8.8
4 8
153 ± 35
5 9
6.3 ± 3.8
[a] DPBF absorbance at 410 nm was observed every 30 s of irradiation (λirr > 500 nm) time over a 4 min time period for methylene blue and compounds 
4 and 6–9. [b] Rates of DPBF degradation by compound 4,6, 7, 8, or 9 are reported as percentages relative to methylene blue (100%). Data are average of three 
independent experiments, errors are standard deviations.
     Intrigued by findings from the EC50 determinations, we sought to gain a better understanding of how 
compound 8 elicits its toxic effect in MDA-MB-231 cells. PCR studies were carried out to look for changes in 
expression of any genetic markers that could be indicative of the nature of the death response. Glucose 
transporter 1, hexokinase 2, lactose dehydrogenase A, and pyruvate dehydrogenase kinase 1, genes involved 
in energy metabolism51 were examined; however, no significant changes in mRNA levels of these markers 
were observed (data not shown). This finding suggests that the combination of 8 and light does not target 
energy metabolism directly. 
     Agents that induce apoptosis usually show little to no cell death at early time points (< 24 h), whereas 
compounds that induce necrosis often display toxicity shortly after treatment.52 To probe the mechanism of 
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cell death, inhibitors of apoptosis and necroptosis were examined. Pretreatment of MDA-MB-231 cells for 2 h 
with the RIP-1 kinase inhibitor necrostatin-1 (50 µM) or the pan-caspase inhibitor Z-VAD-fmk-OMe (20 µM) 
did not provide significant levels of rescue for cells treated with 8 (2.5 µM) and light (t = 15 min, λirr = 460-
470 nm) after 4 h (Figure 3). These data suggest that apoptosis and necroptosis do not play major roles in cell 
death. Consistent with this idea, Western blot analysis also indicated that the executioner enzyme caspase-3 
was not activated at 4 h, indicating that the apoptotic cascade was not operational (Figure S32) 
Figure 3. Cell viabilities determined after 4 h by MTT upon pretreatment with   RIP-1 kinase inhibitor 
necrostatin-1 (Nec, 50 µM) or pan-caspase inhibitor Z-VAD-fmk-OMe ( zVAD, 20 µM) for 2 h, followed by 
vehicle (blue) or 8 (red, 2.5 µM) and light (t = 15 min, λirr = 460–470 nm). Data are representative of three 
independent experiments and are average of quadruplicate wells with error bars as standard deviations.
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      As opposed to rescue experiments shown in Figure 2, strong supporting evidence for rapid necrotic cell 
death was obtained by flow cytometry. Cells treated with 8 (10 µM) and light (t = 15 min, λirr = 460–470 nm) 
showed similar levels of uptake of the cell impermeable dye 7-aminoactinomycin D (7-AAD) after 4 h to cells 
treated with H2O2 (500 mM), a known inducer of necrosis.52 Uptake of 7-AAD is consistent with the loss of 
the plasma membrane integrity that occurs during rapid necrotic death (Figure 4A-E, S24–28). The dye 7-AAD 
was chosen over propidium iodide to avoid emission overlap with the BODIPY fluorophore of 8 and its 
photochemical byproducts, whose contribution to cellular fluorescence in the FL1 channel (516-556 nm) is 
evident in cells treated with 8 (Figure 4B,D), consistent with the cell permeability of 8. Importantly, cells 
treated with 8 (10 µM) in the dark, or with light alone showed minimal 7-AAD uptake (Figure 4D,A).
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Figure 4. Flow cytometric analysis of MDA-MB-231 cells after treatment with A) Vehicle alone 
and light (t = 15 min, λirr = 460–470 nm), 4 h; B) 8 (10 µM) and light (t = 15 min, λirr = 460–470 
nm), 4 h C) H2O2 (500 mM), 3 h; D) 8 (10 µM) in the dark. E) Vehicle in the dark. Cells were 
harvested and stained with the fluorescent DNA stain 7-AAD (λem = 647 nm) which stains 
permeabilized cells, consistent with necrosis. Fluorescence signals (λex = 488 nm) detected were 
FL1 (516–556 nm) and FL3 (665–685 nm). Fluorescence in FL1 channel in Figures 4B and 4D is 
due to 8 and BODIPY-derived photochemical byproducts. Data are indicative of three independent 
experiments. See Supporting information for more details.
     Taking all of these observations into consideration, it is important to consider why 8 elicits 
rapid death in MDA-MB-231 cells at low concentrations, whereas the related analogs 2, 6, 7 and 
9 do not.  Importantly, CTSB regulation the proteolytic network that controls cell death occurs on 
the minute timescale, where 2, the inhibitor of choice for selective CTSB inactivation, has been 
proven to be slowly activated by intracellular esterases and not selective.22, 23 Esterase cleavage of 
2 is likely not rapid enough to generate high intracellular concentrations of 1 needed for CTSB 
inactivation on short time scales that leads to necrosis. Light-activated inhibitor 8 combines the 
ideal properties of 2, which is cell permeable but not selective, with 1, which is impermeable but 
highly selective. The combination of cell permeability, high rate acceleration and selectivity for 
CTSB inactivation under light vs. in the dark makes 8 and its derivatives promising chemical tools 
to dissect proteolytic networks of cell survival and death that occur on short time scales. Further 
photochemical investigations will be needed to understand how the substituent X bound to boron 
controls the efficiency of uncaging for 8 and its derivatives. Based on the tunable reactivity of 
BODIPY-protected esters for photorelease and ROS generation demonstrated in this manuscript, 
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we expect to be able to identify compounds that undergo fast photorelease of biologically active 
carboxylic acids with minimal ROS generation that would serve as good chemical tools.
     In addition to its rapid inactivation of CTSB, BODIPY-caged inhibitor 8 generates 1O2. 
Importantly, our data confirm that 8 generates 1O2 generation more efficiently than methylene 
blue, and that generated 1O2 contributes to cancer cell death. However, control experiments with 
2 and 6 vs. 8 suggest that generation of 1O2 is not the only factor that contributes to cell death. 
Rapid CTSB inactivation may be necessary to steer cells away from apoptosis towards necrotic 
death. The combination of rapid CTSB inactivation with ROS generation is synergistic and may 
be a promising strategy to achieve necrotic cell death in vivo. Due to a myriad of problems 
associated with agents that cause apoptosis in the clinic, including positive selection for resistant 
cancer cells during treatment, there has been a resurgence in the interest of agents that cause death 
by means other than apoptosis. 
Conclusion
     In conclusion, we report the synthesis, photochemical and biological characterization of a series 
of BODIPY-caged CTSB inhibitors. Our data confirm that the photochemical and biological 
properties of these caged inhibitors are highly tunable based on the substituent X bound directly 
to boron. Collectively, this study confirms that the combination of rapid and selective inactivation 
of CTSB with 1O2 generation achieved with 8 leads to a synergistic effect that steers cancer cells 
away from apoptotic death, favoring necrosis. Further studies to understand the chemistry of 8 and 
its analogs, their use as chemical tools to dissect proteolytic networks of cell survival and death, 
as well as the development of light-activated therapeutics based on this strategy are currently 
underway in our laboratories.
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